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Abstract 
Background: Human papillomavirus vaccines have demonstrated remarkable efficacy against 
persistent infection and disease associated with vaccine-incorporated genotypes and a degree of 
efficacy against some genetically related, non-vaccine-incorporated genotypes. The vaccines differ 
in the extent of cross-protection against these non-vaccine genotypes. Data supporting the role for 
neutralizing antibodies as a correlate or surrogate of cross-protection are lacking, as is a robust 
assessment of the seroconversion rates against these non-vaccine genotypes.  
Methods: We performed a systematic review and meta-analysis of available data on vaccine-
induced neutralizing antibody seropositivity to non-vaccine incorporated HPV genotypes.  
Results: Of 304 articles screened, 9 were included in the analysis representing ca. 700 individuals. 
The pooled estimate for seropositivity against HPV31 for the bivalent vaccine (86%; 95%CI 78 – 
91%) was higher than that for the quadrivalent vaccine (61%; 39 – 79%; p=0.011). The pooled 
estimate for seropositivity against HPV45 for the bivalent vaccine (50%; 37 – 64%) was also higher 
than that for the quadrivalent vaccine (16%; 6 – 36%; p=0.007). Seropositivity against HPV33, 
HPV52 and HPV58 were similar between the vaccines. Mean seropositivity rates across non-
vaccine genotypes were positively associated with the corresponding vaccine efficacy data reported 
from vaccine trials.  
Conclusions: These data improve our understanding of vaccine-induced functional antibody 
specificity against non-vaccine incorporated genotypes and may help to parameterize vaccine-
impact models and improve patient management in a post-vaccine setting. 
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Introduction 
Human papillomavirus (HPV) is associated with 5% of all human cancers worldwide and around 
30% of those cancers attributed to infectious agents [1]. The bivalent (Cervarix®) and quadrivalent 
(Gardasil®) prophylactic HPV vaccines comprise virus-like particles (VLP) based upon the major 
capsid protein (L1) of HPV16 and HPV18 [2], which are the two genotypes associated with the 
majority (ca. 70%) of cervical cancers [3]. Gardasil® also contains VLP representing genotypes 
associated with the development of genital warts (HPV6 and HPV11). Both vaccines are highly 
efficacious at preventing persistent infection and cervical cancer precursors associated with HPV16 
and HPV18 in vaccine trials [4-6]. These findings are starting to be reflected in post-licensure impact 
surveillance data following the implementation of national HPV immunization programmes [7]. 
Neutralizing antibodies against HPV16 and HPV18 genotypes can be detected in the serum and 
genital secretions of vaccinees [8], appearing to corroborate pre-clinical animal model data that 
support type-specific protection being mediated by neutralizing antibodies [9-11].  
 
A degree of cross-protection has also been demonstrated in vaccine trials against persistent 
infection and disease associated with some non-vaccine genotypes that are genetically related to 
the vaccine genotypes [4, 12], a phenomenon that is also starting to be seen in vaccinated 
populations [7, 13]. The vaccines exhibit differential efficacy in this respect such that Cervarix® 
appears to be more protective against HPV31 (related to HPV16) than Gardasil® and this difference 
in efficacy is more marked for HPV45 (related to HPV18). These two non-vaccine genotypes alone 
are associated with ca. 10% of cervical cancers [3]. Cross-neutralizing antibodies can be detected in 
the serum and, in one study, the genital secretions of vaccinees [14-20]. These data are derived 
from relatively small immunogenicity studies, using one or both vaccines and carried out in different 
age groups, factors that may affect interpretation of whether the detection of such antibodies may 
be useful as a correlate or surrogate of vaccine-induced cross-protection. This report presents a 
systematic review and meta-analysis of available data on vaccine-induced neutralizing antibody 
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seropositivity to non-vaccine incorporated HPV genotypes in order to provide a robust estimate of 
seroconversion rates against non-vaccine incorporated genotypes.  
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Methods 
Search Strategy and Selection Criteria 
A systematic search was undertaken of PubMed to identify papers reporting seropositivity data in 
conjunction with cross-neutralizing antibody titers against HPV non-vaccine genotypes. A 
combination of the following free terms were used to search titles and abstracts: (“HPV” or “Human 
Papillomavirus”) and “Vaccine” and “Antibod*” and “Neutrali*”. Two of the authors (SLB and AG) 
independently identified papers for analysis that were returned by the search terms up until June 
2016. The a priori exclusion criteria were (i) description of a novel antigen, not a licensed HPV 
vaccine; (ii) description of antibodies elicited by natural infection, not vaccination; (iii) no 
neutralization data were presented; (iv) no cross-neutralization data were presented in the same or 
linked study specific paper; (v) not the primary evaluation of study neutralization data. Papers were 
initially excluded based upon title only, followed by a second round of exclusion based upon 
abstract content. Where the abstract stated or implied the inclusion of neutralization data within the 
published study the full text of the paper was reviewed. 
 
Data Extraction 
Key information retrieved for analysis included: participant characteristics (sex, age group), study 
characteristics (study setting, vaccine(s) used, sample collection times) and assay characteristics 
(assay format, target antigens, seropositivity, titers). The primary outcome measure was 
seropositivity to the two oncogenic vaccine incorporated genotypes (HPV16 and HPV18) and five 
non-vaccine incorporated genotypes (HPV31, HPV33, HPV45, HPV52 and HPV58) for which both 
efficacy and seropositivity have been consistently evaluated. The secondary outcome measure was 
the antibody titer to vaccine (HPV16, HPV18) and non-vaccine genotypes (HPV31, HPV45). Two of 
the authors (SBL and AG) performed the data extraction into a template spreadsheet and a data 
integrity check was performed (SB) before use.  
 
Statistical methods 
Estimates of seropositivity to each genotype following vaccination with either Gardasil® or 
Cervarix® were pooled using a DerSimonian-Laird random effects model, with logit transformed 
outcome variables. Cochran’s Q-test was used as a test of interaction to see if the type of vaccine 
(or other variable) had a significant impact on seropositivity by genotype. 
 
The association between vaccine efficacy (against persistent infection and CIN2+) as reported from 
clinical trials [12] and the mean seropositivity generated in this study was investigated. To propagate 
the uncertainty in these variables to the uncertainty in the linear relationship, we used a resampling 
technique known as the bootstrap [21]. To do this, we randomly sampled with replacement 1000 
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times from the set of positive and negative individuals in the populations of the studies used to 
estimate efficacy and seroprevalence. Each random sample was then used to construct a related 
estimate of vaccine efficacy, to construct a set of 1000 bootstrap estimates of vaccine efficacy. This 
was associated to 1000 similarly constructed estimates of seroprevalence using linear regression. 
 
Vaccine efficacy and seropositivity were plotted on graphs. The uncertainty in the graphs represents 
the 95% range of predictions across the models. Exact 95% confidence intervals for data points 
were calculated using the Fisher’s exact method for vaccine efficacy (1-odds ratio) and Clopper-
Pearson for seroprevalence. Significance was taken at the 5% level and 95% confidence intervals 
used. Two-sided significance tests were used. R version 3.1.2 (R Development Core Team) was 
used for the analyses. 
 
Results 
We identified 304 articles of which 9 (representing 7 discrete studies) were included for this analysis 
(Figure 1) [14-20, 22, 23]. Details on the individual studies can be found in Table 1. All studies 
included females (>95% of total assessed population) while one study [18, 23] also included males. 
Three studies [14, 16, 19] included adolescent girls at the approximate target age for vaccination 
(11 - 15 years old) while four studies [15, 17, 18, 20, 22, 23] included women over 18 years of age. 
Two studies [16, 19] collected serum from adolescent girls taking part in national vaccination 
programmes, while five studies [14, 15, 17, 18, 20, 22, 23] collected serum from individuals in the 
context of a vaccination trial. Post-vaccination seropositivity was assessed at month 7 (1 month post 
third vaccine dose; M7) [14, 17, 18, 20, 22, 23], month 12 (6 months post third vaccine dose; M12) 
[14-16, 18, 20, 23], or in one study [19], using data collected between month 7 and month 12. All 
studies [14-20, 22, 23] evaluated Cervarix® vaccinees while five studies [14, 17-20, 22, 23] also 
included Gardasil® vaccinees. All studies [14-20, 22, 23] used HPV pseudovirus targets HPV16, 
HPV18, HPV31 and HPV45 in neutralizing antibody tests with five studies [14-16, 18, 20, 23] 
including one or more additional Alpha-7 (related to HPV18) and Alpha-9 (related to HPV16) 
genotypes.  
 
Seropositivity against HPV16 and HPV18 was essentially 100% following three doses of either 
Cervarix® or Gardasil® vaccine; a slightly lower (98%) HPV18 seropositivity was reported by one 
study following Gardasil® vaccination (data not shown). A higher proportion of Cervarix® vaccinees 
(86%; 95%CI 78 – 91%; pooled estimate using the random effects model) were seropositive against 
HPV31 than Gardasil® vaccinees (61%; 39 – 79%; p=0.011) (Figure 2). Cervarix® vaccinees (50%; 
37 – 64%) also exhibited a markedly higher proportion of seropositivity against HPV45 than 
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Gardasil® vaccinees (16%; 6 – 36%; p=0.007). Pooled estimates for seropositivity against HPV33, 
HPV52 and HPV58 demonstrated no significant difference between the vaccines.  
 
One of these studies [18, 23] examined bivalent and quadrivalent vaccine immunogenicity in a 
cohort of human immunodeficiency virus (HIV-1) infected individuals. Pooled estimates for 
seropositivity against HPV31 (Cervarix®: 87%; 95%CI 78 – 92%; Gardasil®: 63%; 38 – 83%; 
p=0.027) and HPV45 (Cervarix®: 47%; 33 – 62%; Gardasil®: 11%; 4 – 28%; p=0.002) not including 
these individuals were similar to the overall estimates.  
 
There was a significant positive association between the overall seropositivity rates against non-
vaccine incorporated genotypes and the vaccine efficacy data [12] against 6 month persistent 
infection (mean line coefficient 1.017; 95% range 0.100 – 2.241; Figure 3a) and positive but non-
significant association with cervical intraepithelial neoplasia grade 2 or greater (CIN2+) (mean line 
coefficient 1.781; 95% range -0.636 – 9.212; Figure 3a) reported from vaccine trials.  
 
These immunogenicity studies were carried out in adolescent girls (<18 years old) and adults (18 
years or older) and included samples collected between one (M7) and six (M12) months after the 
third dose of vaccine. There were too few studies to allow a subset analysis, whereby the influence 
of vaccine, age group, and sampling time on genotype-specific seropositivity could be evaluated 
independently. Instead, seropositivity to HPV31 or HPV45 was evaluated using age group 
(irrespective of vaccine and sampling time) and sampling time (irrespective of vaccine and age 
group) as composite variables (Supplementary figure). This was a similar approach to that taken 
for the evaluation of seropositivity stratified by vaccine, irrespective of age group and sampling time 
(Figure 2). The pooled estimate for seropositivity against HPV31 in the adolescent age group (87%; 
71 – 95%) was slightly higher than that achieved in adults (66%; 50 – 80%; p=0.045). Seropositivity 
against HPV45 for adolescents (31%; 15 – 52%) was similar to that in adults (38%; 19 – 61%; 
p=0.613). Overall, seropositivity against HPV31 (M7: 76%; 57 – 89% vs. M12: 81%; 65 – 91%; 
p=0.636) and HPV45 (M7: 35%; 19 – 56% vs. M12: 51%; 33 – 69%; 0.268) was similar regardless 
of sampling time.  
 
The magnitude of the vaccine antibody responses were reported as the median or geometric mean 
titers for both vaccine (HPV16 and HPV18) and non-vaccine (HPV31 and HPV45) genotypes. 
Although the magnitude of the titers for both vaccine and non-vaccine genotypes varied widely 
between studies, the non-vaccine genotype titers appeared to track their respective vaccine-type 
titers with some consistency (Figure 4). HPV16 titers were a median 170 (inter-quartile range, IQR, 
134 - 262) fold higher than HPV31 titers for Cervarix® and a median 337 (201 - 365) fold for 
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Gardasil®. HPV18 titers were a median 478 (296 - 1,413) fold higher than HPV45 titers for 
Cervarix® and a median 146 (108 - 1,377) fold for Gardasil®.  
 
Discussion 
We performed a systematic review and meta-analysis of available seropositivity data against non-
vaccine genotypes representing seven studies and approximately seven hundred individuals 
vaccinated with three doses of either Cervarix® or Gardasil® HPV vaccine [14-20, 22, 23].  
 
The estimated seroconversion rate for neutralizing antibodies against HPV31 was higher than that 
for HPV45, with Cervarix® vaccinees exhibiting higher rates of seroconversion against both of these 
genotypes than Gardasil® vaccinees. For HPV33, HPV52 and HPV58 the seroconversion rates 
were similar between the vaccines. There was a strong association between the seropositivity rates 
for these non-vaccine genotypes and the efficacy data reported from HPV vaccine trials [24, 25]. 
HPV31 seropositivity has been shown to be coincident with a reduced risk of HPV31 acquisition 
post-vaccination with Cervarix®, although data supporting a similar relationship for HPV45 and 
HPV58 were lacking [26].  
 
This review incorporated data from adolescent girls around the target age for vaccination in national 
immunization programmes and from older women and included data collected between one and six 
months after the third vaccine dose. Of these variables, only the younger age at vaccination was 
shown to be associated with a higher seropositivity against HPV31. Where individual studies have 
compared the immune response to HPV vaccines in populations of similar ages, and using samples 
collected at the same time point post-vaccination, they have consistently demonstrated higher rates 
of seroconversion and/or higher titers against both HPV16 and HPV18 [14, 20, 22, 23] and non-
vaccine genotypes [14, 17, 18, 20] following Cervarix® vaccination. Similarly, where studies 
compared serological responses between one and six months following the third vaccine dose, a 
small decline in seropositivity and/or titers was seen for both adolescents [14] and older women [17, 
18, 20, 22, 23]. The issue of age is more problematic. Only one study in this review examined age-
dependent immune responses against vaccine and non-vaccine genotypes by stratifying a cohort of 
18 – 45 year old mid adult women into three sub-groups (18 – 26, 27 – 35 and 36 – 45 years) and 
demonstrated some degree of age-related influence on responses against vaccine genotypes [22], 
but the influence on responses against non-vaccine genotypes was less clear [17]. A stronger 
serological response elicited in adolescents compared to adult women has been demonstrated for 
both vaccines [27-30], but only against vaccine-incorporated genotypes using binding assays. The 
removal of data from one study [18, 23] comprising HIV-infected subjects made little difference to 
the pooled estimates for seropositivity against HPV31 and HPV45 suggesting, based on these 
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limited study data, that the HIV serostatus of vaccine recipients may have little impact on HPV 
vaccine immunogenicity [31].  
 
The magnitude of the neutralizing antibody response varied between studies with responses against 
non-vaccine genotypes at least two orders of magnitude lower than those elicited against vaccine-
incorporated genotypes. The long-term durability of cross-neutralizing antibodies is unclear; thus far, 
antibodies against HPV31 and HPV45 have been detected out to twenty-four months post-
vaccination [17, 22]. In the same vaccine comparison study, responses against HPV16 and HPV18 
remain robust out to 5 years [32].  
 
There are several shortcomings to this study. The small number of available studies limited a robust 
evaluation for some non-vaccine genotypes, notably HPV33, HPV52 and HPV58. This is particularly 
true for estimating seroconversion rates for Gardasil® vaccinees, which were represented by a 
single study or pair of studies in some cases. The small number of available studies also precluded 
an analysis of the influence of each variable (vaccine, age group, sampling time) independently. 
Thus, the differences in seropositivity due to the vaccine may have been confounded by the 
influence of the age at vaccination and the sampling time post third dose. This confounding likely led 
to the high heterogeneity scores seen here and potentially obscured more subtle effects of age and 
sampling time on seropositivity.  
 
This review evaluated studies incorporating a three-dose schedule. Reduced dose arms in vaccine 
trials have demonstrated non-inferior seropositivity to vaccine genotypes and similar vaccine 
efficacy [33, 34], resulting in a recommendation for a two dose schedule to be adopted worldwide 
[35]. However, reduced seropositivity to HPV31 has been demonstrated for less than three doses 
[36], which is likely to be a factor in the reduced vaccine efficacy observed against non-vaccine 
genotypes HPV31 and HPV45 in a post-hoc analysis of Cervarix® trial data [37]. Nevertheless, this 
report represents an analysis of the only available functional data with which to evaluate 
seroconversion rates against non-vaccine incorporated genotypes.  
 
Recently, the nonavalent Gardasil®9 vaccine comprising additional genetically related genotypes 
HPV31, HPV33, HPV45, HPV52 and HPV58 has demonstrated efficacy in a three dose schedule 
[38] and non-inferiority of antibody responses for two doses [39]. A nonavalent vaccine has the 
potential to reduce the incidence of cervical cancer by over 90% [3, 40], is expected to be cost 
effective [41, 42]. Nonavalent vaccine efficacy against persistent infection or low grade disease 
associated with any of these additional genotypes in the per protocol population was ≥96% which is 
considerably higher than any beneficial cross-protective vaccine efficacy induced by either the 
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bivalent or quadrivalent vaccines against these genotypes [24, 25, 43]. Although national 
immunization programmes will likely adopt the nonavalent vaccine in time, to date tens of millions of 
adolescent girls have been vaccinated with the bivalent or quadrivalent vaccine [44], for which a 
better understanding of their immunogenic properties including the seroconversion rates, breadth, 
magnitude and durability of the antibody responses against vaccine and non-vaccine genotypes is 
warranted.  
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Figure 1. Flowchart of the study selection process 
 
Figure 2. Pooled estimates for seroconversion against non-vaccine incorporated genotypes 
Estimates of seropositivity to each genotype following vaccination with either Gardasil® or 
Cervarix® pooled using a DerSimonian-Laird random effects model, with logit transformed outcome 
variables. Test for subgroup differences using Cochran’s Q-test.  
 
Figure 3. Comparison of neutralizing antibody seropositivity and reported vaccine efficacy 
Mean seropositivity data from this meta-analysis, derived using the random effects model are 
plotted against (a) efficacy against persistent infection and (b) efficacy against CIN2+ reported from 
trials of Cervarix® (blue points) and Gardasil® (red points) vaccinees for each non-vaccine HPV 
type (HPV31, HPV33, HPV45, HPV52 and HPV58). Vertical error bars represent exact 95% 
confidence intervals for the efficacy data, while horizontal error bars represent exact 95% 
confidence intervals for the neutralization seropositivity data. The best fitting linear relationship 
between the two variables (black line) and the 95% range of bootstrap estimates for this relationship 
(dotted lines) is also shown. Exact 95% confidence intervals for data points were calculated using 
the Fisher’s exact method for vaccine efficacy (1-odds ratio) and Clopper-Pearson for seropositivity. 
 
Figure 4. Vaccine and non-vaccine neutralizing antibody titers 
Neutralizing antibody titers against (a) HPV16 (dark shade) and HPV31 (light shade) and (b) HPV18 
(dark shade) and HPV45 (light shade) for Cervarix® (blue) and Gardasil® (red) vaccinees. First 
author name and year of publication given for each article with target age group (G, girls <18 years; 
W, women 18 or more years old) and sampling time (7 or 12 months post first dose; 7+ represents a 
range from 7-12 months for one study). Data represent the geometric mean (95%CI) neutralizing 
antibody titers apart from Kemp (2011) and Draper (2011) which represent the median (IQR) 
neutralizing antibody titers. Size of data points reflect approximate sample sizes in each study.  
 
Supplementary Figure. Pooled estimates for age group and sampling time 
Pooled estimates of seropositivity to (a, c) HPV31 and (b, d) HPV45 stratified by (a, b) age group or 
(c, d) sampling time following vaccination with either Cervarix® (denoted by an asterisk) or  
Gardasil® using a DerSimonian-Laird random effects model, with logit transformed outcome 
variables. Test for subgroup differences using Cochran’s Q-test.  
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Table 1. Study characteristics 
Author Year Sex 
Age 
group 
a
 
Medical 
exclusion 
criteria 
Setting HPV status 
Vaccines 
assessed 
Months 
post 1st 
dose 
HPV targets Reporter 
b
 
Assay 
threshold 
c
 
No. sera per 
target  
(Min – Max) 
d
 
Kemp 2011 F 18 - 25 Yes Trial Unselected Cervarix® M12 
16 18 31 45 52 
58 
seAP 10 (50%) 46 
Draper 2011 F 13 - 14 No Programme Unselected Cervarix® M12 
16 18 31 33 45 
52 58 
Luc 20 (80%) 69 
Einstein 2011 F 18 - 26 Yes Trial 
Seronegative 
and DNA 
negative 
Cervarix® 
and 
Gardasil® 
M7 16 18 31 45 seAP 40 (50%) 103 - 131 
Draper 2013 F 12 - 15 Yes Trial Unselected 
Cervarix® 
and 
Gardasil® 
M7 & M12 
16 18 31 33 45 
52 58 
Luc 20 (80%) 91 - 97 
Toft 2014 MF >18 Yes Trial 
Seronegative 
and DNA 
negative 
Cervarix® 
and 
Gardasil® 
M7 & M12 16 18 31 33 45 Luc 40 (50%) 12 - 26 
Barzon 2014 F 11 - 13 Yes Programme Unselected 
Cervarix® 
and 
Gardasil® 
M7 - M12 16 18 31 45 seAP 40 (50%) 50 - 126 
Herrin 2015 F 18 - 25 Yes Trial Unselected 
Cervarix® 
and 
Gardasil® 
M7 & M12 16 18 31 45 58 seAP 10 (50%) 7 - 12 
a 
Age range of participants except for Toft_2014 where median ages of Cervarix® vaccinees (47.0; IQR 38.6 – 54.2) and Gardasil® (44.5; 38.2 – 51.9) were given. 
b 
Assay readout makes use of Luciferase (Luc) or Secreted embryonic alkaline phosphatase (seAP) reporter gene expression 
c 
Assay threshold defined by lowest antibody titer considered positive and in parentheses the percentage reduction in reporter activity required to be considered positive 
d 
Number of serum used varies in some studies so numbers are presented as the minimum used (against any target type for any vaccine) to the maximum used. 
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